Sequencing of Stereotactic Ablative Body Radiation Therapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma

Titre officiel

Sequencing of Stereotactic Ablative Body Radiation Therapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma

Sommaire:

This investigator driven Phase Ib study will examine the safety, efficacy and biological effects of two schedules of pembrolizumab, an antibody targeted against anti-programmed cell death 1 (PD-1), which will be given either before or after stereotactic ablative body radiation therapy (SABR) for metastatic NSCLC.

Description de l'essai

Primary Outcome:

  • Adverse events measured using CTCAE version 4.03
Secondary Outcome:
  • Overall response assessed using RECIST 1.1
  • Overall response assessed using irRECIST
  • Overall response assessed using PERCIST1.0
  • Overall response assessed using Peter Mac Metabolic Response Criteria
  • Overall survival
  • Progression free survival (PFS)

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer